Compare CXDO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXDO | ACIU |
|---|---|---|
| Founded | 1995 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.9M | 229.7M |
| IPO Year | 1999 | 2015 |
| Metric | CXDO | ACIU |
|---|---|---|
| Price | $6.10 | $2.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $10.92 | $8.57 |
| AVG Volume (30 Days) | 172.0K | ★ 195.8K |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 166.67 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $68,167,000.00 | N/A |
| Revenue This Year | $42.60 | $422.39 |
| Revenue Next Year | $13.69 | $377.85 |
| P/E Ratio | $123.60 | ★ N/A |
| Revenue Growth | ★ 12.05 | N/A |
| 52 Week Low | $5.35 | $2.03 |
| 52 Week High | $11.23 | $3.90 |
| Indicator | CXDO | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 58.62 | 41.75 |
| Support Level | $5.96 | $2.13 |
| Resistance Level | $6.71 | $2.41 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 88.49 | 64.65 |
Crexendo Inc is a software technology company that provides cloud communication platform software and unified communications as a service (UCaaS) offering, including voice, video, contact center, and managed IT services. The company operates through two segments: Cloud Telecommunications Services and Software Solutions. Its cloud telecommunications segment generates revenue from the provision of broadband Internet services, managed IT services, software license sales, and infrastructure as a service. The software solutions segment derives revenues from three primary sources: software licenses, software maintenance support and professional services. The majority of the company's revenue is derived from the Cloud Telecommunications Services segment.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.